Novavax, Inc. (NASDAQ:NVAX) Earns "Neutral" Rating from Chardan Capital


Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement. American International Group Inc. owned about 0.06% of Novavax worth $213,000 as of its most recent filing with the SEC. The analysts, on average, are forecasting a $3 price target, but the stock is already up 19.63% from its recent lows. NY raised its position in shares of Novavax by 2.9% in the fourth quarter. NY now owns 203,996 shares of the biopharmaceutical company's stock valued at $257,000 after buying an additional 5,704 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Novavax during the first quarter valued at about $157,000. Finally, JPMorgan Chase & Co. boosted its stake in Novavax by 41.9% in the first quarter. The stock exchanged hands 2.29 Million shares versus average trading capacity of 7.12 Million shares. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 8,966 shares in the last quarter. Institutional investors and hedge funds own 50.49% of the company's stock. The stock stands almost -88.1% off versus the 52-week high and 38.36% away from the 52-week low.

On the other hand, Novavax, far traveled 38.36% versus a 1-year low price of $0.73.

Sometimes, we can understand most about a stock by simply looking at how it has been trading. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The stock's market capitalization is $292.80 million.

Investors and Traders continue to monitor technical levels of shares of Novavax, Inc. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16). Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. For the current year the company's revenue estimates are $26.06 Million compared to low analyst estimates of $22 Million and high estimates of $29.4 Million according to the prediction of 6 analysts.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, August 8th. During the same quarter past year, the business posted ($0.29) EPS. On average, equities research analysts expect that Novavax will post ($0.62) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & worldwide copyright law. The legal version of this report can be accessed at BidaskClub lowered Novavax from a "hold" rating to a "sell" rating in a research report on Wednesday, July 19th. Zacks Investment Research raised shares of Novavax from a hold rating to a buy rating and set a $1.25 price target for the company in a research report on Saturday, June 10th.



Related Posts

Housing Starts Tumble in July, Down 4.8%
This is 4.8% below the revised June estimate of 1,213,000 and is 5.6% below the July 2016 rate of 1,223,000. The revision to the June rate dropped 2,000 new housing starts from the previously reported total.

Six Killed In Guatemala Hospital Attack
The high-ranking official asked judges not to authorize further transfers of highly unsafe prisoners to the country's hospitals. Via Twitter, the agency showed photographs of assault rifles seized from the attackers.

Daily Stormer Booted From Russia for 'Propagandizing Neo-Nazi Ideology'
The move followed a request from Roskomnadzor, the Russian government's media and telecommunication watchdog, Timofeev said. He's now facing a defamation lawsuit filed in Columbus by a well-known Muslim comedian, columnist and radio host.

Activision Blizzard Target of Unusually High Options Trading (NASDAQ:ATVI)
Now we will discuss the financial strength of Activision Blizzard, Inc . (NASDAQ:ATVI) on Wednesday, June 7 with "Buy" rating. Kelly sold 111,239 shares of the company's stock in a transaction on Monday, August 7th. (NASDAQ:ATVI) or 420,063 shares.

OSCE MG preparing Azerbaijani, Armenian presidents' meeting
She noted that the Minsk Group co-chairs are now working on the organization of the next meeting of the presidents. The 1994 ceasefire agreement was followed by peace negotiations.

Endo International PLC (NASDAQ:ENDP) Sets New 12-Month Low at $9.67
According to analysts Endo Int'l Plc (NASDAQ:ENDP)'s minimum EPS for the current quarter is at $0.55 and can go high up to $0.71. Finally, BidaskClub upgraded Endo International PLC from a "sell" rating to a "hold" rating in a report on Wednesday, July 19th.

These Gaudy Nike Air Max 97s Have 55690 Swarovski Crystals on Them
A women's style, the Nike Air Max 97 pictured uses Crystal Fabric to add a brilliant layer to the original runner. As the shoe moves, the crystals refract light with a bright, shimmering effect.

Essent Group Senior Vice President Sold $15327.00 in Shares
The institutional investor purchased 9,247 shares of the financial services provider's stock, valued at approximately $334,000. Its products and services include mortgage insurance, contract underwriting, and Bermuda-based insurance and reinsurance.

Rachel Lindsay Regrets Picking Bryan Abasolo Over Peter Kraus: Bachelorette Mistake?
The duo have admitted they're still stuck between Abasolo's hometown in Miami, Lindsay's roots in Dallas or trying somewhere new. Because of this, Celeb Dirty Laundry speculated that the Rachel could possibly be having second thoughts about marrying Bryan.

Mauricio Pellegrino: 'No change on Virgil van Dijk status'
Join the Saints Marching team! Van Dijk did not feature in Saturday's Premier League opener against Swansea because of a virus. That goes without question because of the quality that he's got".

© 2015 ExpressNewsline. All Rights reserved.